Join

Store

Chapters

APIC Action Center

Our Action Center makes it easy to action send a relevant letter to your legislators in seconds.

Take Action Now
Menu

Policy Updates

Check insights and updates from APIC!

CDC HAN Advisory: COVID-19 Rebound After Paxlovid Treatment
05/25/2022
CDC HAN Advisory: COVID-19 Rebound After Paxlovid Treatment

5/24/22 — The CDC issued a Health Alert Network (HAN) Health Advisory to update healthcare providers, public health departments, and the public on the potential for recurrence of COVID-19 or “COVID-19 rebound.” Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease. Paxlovid treatment … Continued

Read More
AHRQ Technical Brief: Emergency Medical Service/911 Workforce Infection Control and Prevention Issues
05/25/2022
CDC/ASPR Listening Session on Proposed Update to CMS CoP on Pandemic Reporting
05/25/2022
CDC/ASPR Listening Session on Proposed Update to CMS CoP on Pandemic Reporting

5/17/22 — The CDC and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) are holding virtual listening sessions on the proposed revision to hospital and critical access hospital Conditions of Participation (CoP) on hospital data reporting provisions for COVID-19 after the conclusion of the current public health emergency (PHE), as well as … Continued

Read More
CDC Updates COVID-19 Pediatric Operational Planning Guide
05/25/2022
CDC Updates COVID-19 Pediatric Operational Planning Guide

5/17/22 — In anticipation of a COVID-19 vaccine for the under-5 population, CDC has updated the Pediatric Operational Planning Guide. Read the updated COVID-19 Vaccination for Children page on the CDC website. Access a direct link to the PDF of the guide.

Read More
FDA Expands Eligibility for Pfizer COVID Vaccine Booster Dose for Children Ages 5-11
05/25/2022
FDA Expands Eligibility for Pfizer COVID Vaccine Booster Dose for Children Ages 5-11

5/17/22 — The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to authorize the use of a single booster dose for individuals 5 to 11 years of age at least 5 months after completion of a primary series with the Pfizer vaccine. Read the FDA announcement.

Read More
Fagron Recalls SyrSpend SF Cherry Due to Microbial Contamination
05/25/2022
Fagron Recalls SyrSpend SF Cherry Due to Microbial Contamination

5/13/22 — Fagron, Inc. is voluntarily recalling two lots of SyrSpend SF Cherry to the hospital, pharmacy, and distributor level out of an abundance of caution. The affected lots are potentially contaminated with Burkholderia gladioli. Fagron sells this product for the extemporaneous compounding of prescriptions for oral dosing. Exposure to contaminated product could lead to adverse events, which … Continued

Read More
Woodside Acquisitions Recalls COVID-19 Antigen Tests
05/25/2022
Woodside Acquisitions Recalls COVID-19 Antigen Tests

5/16/22 — Woodside Acquisitions Inc. is recalling the Oral Rapid SARS-CoV-2 Antigen Rapid Test Kit and the Joysbio SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) because they were distributed to U.S. customers without authorization, clearance, or approval from the FDA. Read the FDA recall notice.

Read More
CDC HAN Alert: Updated Recommendations for Adenovirus Testing in Children with Hepatitis
05/25/2022
CDC HAN Alert: Updated Recommendations for Adenovirus Testing in Children with Hepatitis

5/11/22 — The CDC is issuing a Health Alert Network (HAN) Health Update to provide updated information and recommendations about an epidemiologic investigation of pediatric cases of hepatitis of unknown etiology in the United States. As of May 5, 2022, CDC and state partners are investigating 109 children with hepatitis of unknown origin across 25 states … Continued

Read More
Skippack SARS-CoV-2 Antigen Rapid Test Recalled
05/25/2022
Skippack SARS-CoV-2 Antigen Rapid Test Recalled

5/10/22 — SML Distribution LLC is recalling the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Tests (Colloidal Gold). The FDA has identified this issue as a Class I recall, the most serious type of recall, because this test is not authorized, cleared, or approved by the FDA for distribution or use in the United States. The FDA … Continued

Read More